Beyond the cholinergic hypothesis: The effect of metrifonate andother cholinesterase inhibitors on neuropsychiatric symptoms inAlzheimer's disease
D. Kaufer
Bok Engelsk 1998
| Utgitt | 1998
|
|---|---|
| Omfang | Side 8- 14
|
| Opplysninger | Preliminary studies suggest that non-cognitive behavioural andpersonality alterations in Alzheimer's disease may benefit fromagents which inhibit central acelylcholinesterase (AChE). A double-blind, placebo-controlled, 26-week study of the AChE inhibitormetrifonate using the NeuroPsychiatric Inventory (NPI) to assess theeffects of treatment on neuropsychiatric symptoms observedstatistically significant mean change differences favouring treatmentin the total NPI score and in symptoms of depression, apathy andhallucinations, as well as a nearly significant difference inaberrant motor behaviours, These data are consistent with previousstudies and are believed to represent the first large prospective,controlled study demonstrating a beneficial effect of AChE inhibitortherapy on neuropsychiatric symptoms in Alzheimer's disease. Thenature of non-cognitive symptom responses to AChE Inhibitor therapyand their potential impact on caregivers is discussed.
|
| Emner |
